Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been administered to the first subject in a Phase I clinical trial. This makes BA1202 the first CEA/CD3 bispe...
Boan Biotech (6955.HK) announced its 2023 half year results and recent developments on August 27, 2023.Highlights of 2023 half year resultsRobust revenue growthIn the first half of 2023, the company&r...